IFIT2 and melanoma: Melanoma patients lacking clinical responses to the anti-CTLA-4 immunotherapeutic, ipilimumab (as compared to those who had such responses) harbored a much higher rate of genomic defects in the IFN-γ pathway genes, including genetic losses of IFIT1, IFIT2 and IFIT3 [22].